Home > Dermatology > EADV 2020 > Best of the Posters > Real-world data on brodalumab affirms efficacy and fast onset of action

Real-world data on brodalumab affirms efficacy and fast onset of action

Presented By
Dr Ralph Von Kiedrowski
Conference
EADV 2020
Trial
LIBERO
A German study investigated the performance of brodalumab for the treatment of psoriasis in real-world conditions. They found meaningful responses as of week 2 and the highest clearance rates was observed in biologic-naïve patients. Brodalumab has shown remarkable efficacy and fast onset of action in psoriasis patients in clinical phase 3 trials [1,2]. The current LIBERO trial aimed to assess how these results translate into a patient population encountered in the daily practice [1]. The ongoing, prospective, non-interventional study investigates the real-world evidence of brodalumab in disease management of psoriasis after 12 and 52 weeks. Data of over 500 patients was obtained between November 2017 and January 2020 from 216 German study centres on the effect of brodalumab on the absolute Psoriasis Area Severity Index (aPASI). Dr Ralph Von Kiedrowski (Germany) presented the 12-week results of the study at the 29th EADV Congress [3]. The ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on